KURA — Kura Oncology, Inc.

Kura Oncology, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Product Revenue: $2.1 million from Comzifty sales in the final weeks of 2025, compared to none in 2024.
• Collaboration Revenue: $15.2 million from Kyowa Kirin, down from $53.9 million in 2024.
• R&D Expenses: Increased to $64.4 million from $52.3 million in 2024, driven by ziftomenib combination trials.
• SG&A Expenses: Rose to $39.1 million from $24.1 million in 2024 due to the commercial launch of Comzifty.
• Net Loss: $81 million, compared to a net loss of $19.2 million in 2024.
• Cash Position: $667.2 million as of December 31, 2025, down from $727.4 million in 2024, but sufficient to fund operations through anticipated milestones.

2. Strategic Updates and Business Highlights

• FDA Approval: Comzifty received FDA approval and initiated a successful commercial launch.
• Market Positioning: Kura aims to establish Comzifty as a leader in the menin inhibitor class, particularly for relapsed/refractory NPM1-mutant AML.
• Clinical Development: Enrollment is underway in pivotal COMET-017 frontline trials, with a focus on expanding into combination therapies and solid tumors.
• Partnerships: Strong collaboration with Kyowa Kirin, with rapid payer engagement leading to high coverage rates (84% of private payers aligned with the label within 90 days).
• Differentiation: Comzifty's safety profile and ease of use are highlighted as competitive advantages over other menin inhibitors.

3. Forward Guidance and Outlook

• Collaboration Revenue Guidance: Expected to be $45 million to $55 million in 2026, $90 million to $110 million in 2027, and $90 million to $110 million in 2028.
• Market Opportunity: The total U.S. market opportunity for AML is estimated at approximately $7 billion, with initial revenue potential for NPM1 relapsed/refractory AML at $350 million to $400 million annually.
• Clinical Updates: Multiple data readouts anticipated in 2026, including updates on combination therapies and the ongoing development of ziftomenib.

4. Bad News, Challenges, or Points of Concern

• Net Loss: The significant increase in net loss raises concerns about the sustainability of current spending levels without immediate revenue growth.
• R&D and SG&A Increases: Rising expenses could pressure future profitability if revenue growth does not accelerate.
• Market Penetration Risks: While initial feedback is positive, the long-term market share will depend on successful combination therapy data and overcoming prescriber inertia.
• Competitive Landscape: The menin inhibitor class is competitive, and Kura must demonstrate superior efficacy and safety in combination settings to maintain its market position.

5. Notable Q&A Insights

• Step Editing by Payers: Some payers are implementing a step edit requiring patients to use Comzifty before other menin inhibitors, indicating strong market confidence in Comzifty's profile.
• Patient Demand: Early demand for Comzifty is strong, with positive feedback from physicians and pharmacists regarding its efficacy and safety profile.
• Combination Therapy Potential: Kura is focusing on combinations with venetoclax and FLT3 inhibitors, which could significantly enhance market penetration and patient outcomes.
• Duration of Therapy: While it's early to assess, the expectation is that patients could be treated for an average of six months, with potential for longer durations when combined with other therapies.

Overall, Kura Oncology is positioned for growth in 2026 with a strong product launch and strategic initiatives, but faces challenges related to financial sustainability and competitive pressures in the oncology market.